Ipamorelin + CJC-1295 Stack: Complete Protocol, Doses, and Timing

Why Combine Ipamorelin and CJC-1295?

Stacking these two peptides targets the same endpoint, a rise in endogenous growth hormone, but through distinct receptor pathways. Ipamorelin binds GHSR-1a (the ghrelin receptor) in the pituitary and hypothalamus, prompting a clean GH pulse with very little spillover into cortisol or prolactin secretion [1]. CJC-1295 mimics growth hormone-releasing hormone (GHRH) at its own receptor, amplifying the magnitude of each GH pulse and, in the DAC-conjugated form, dramatically extending the plasma half-life [2].

Animal studies show the combination produces additive to synergistic GH elevation compared with either agent alone [3]. The physiological rationale matches what endocrinologists already know: endogenous GHRH and ghrelin act on separate receptors that converge on the same pituitary somatotroph signaling cascade, and co-administration of a GHRH analogue with a ghrelin mimetic reliably amplifies GH output more than either stimulus alone [4].

The Two-Signal Model

Think of pituitary somatotrophs as needing two inputs before releasing a full GH pulse. GHRH (mimicked by CJC-1295) primes the cell and increases cAMP. Ghrelin-pathway activation (mimicked by ipamorelin) provides the second signal that tips the cell into active secretion. Neither signal alone is as effective as both together, which is the core pharmacological justification for the stack [4].

Evidence Gaps to Acknowledge

No phase II or phase III RCT has evaluated the ipamorelin-plus-CJC-1295 combination in healthy adults for body composition. What exists includes: a published pharmacokinetic RCT of CJC-1295 alone showing dose-dependent GH and IGF-1 elevation [2], ipamorelin pharmacokinetic studies showing peak GH at 15 to 30 minutes post-injection [1], and mechanistic work showing GHRP-plus-GHRH combination in animal models [3]. Practitioners synthesize these data into clinical protocols, but that extrapolation carries uncertainty.

How Each Peptide Works

Ipamorelin: Mechanism and Selectivity

Ipamorelin (NNC 26-0161) is a pentapeptide GHRP developed in the 1990s. Its main pharmacological advantage over older GHRPs such as GHRP-6 is selectivity. At doses up to 200 mcg/kg in animal studies, ipamorelin produced no statistically significant rise in ACTH, cortisol, or prolactin [1]. That selectivity profile is one reason practitioners prefer it for longer cycles where cortisol elevation would be counterproductive to body composition goals.

Peak serum GH occurs roughly 15 to 30 minutes after subcutaneous injection, and the GH pulse returns toward baseline within 90 to 120 minutes [1]. The short pulse shape mimics normal physiological GH release, which is relevant because sustained GH elevation, rather than pulsatile release, is associated with insulin resistance and acromegalic side effects [5].

CJC-1295: Half-Life Engineering

Native GHRH(1-44) has a plasma half-life under 10 minutes due to rapid DPP-IV cleavage [2]. CJC-1295 is a modified GHRH analogue engineered at positions 2, 8, 15, and 27 to resist that degradation. The version without the Drug Affinity Complex (DAC) modification, sometimes called modified GRF(1-29) or "CJC-1295 no-DAC," has a half-life of approximately 30 minutes. The DAC-conjugated form achieves albumin binding that extends the half-life to approximately 6 to 8 days [2].

A published RCT by Teichman et al. (N=65) showed that a single injection of CJC-1295 DAC at 60 mcg/kg produced sustained GH elevation for 6 days and increased IGF-1 levels by 28 to 89% above baseline, persisting for up to 28 days after multiple doses [2]. That trial provides the strongest human pharmacokinetic anchor for the DAC protocol.

Dosing Protocols

The two main protocol designs differ based on which CJC-1295 form is used.

Protocol A: CJC-1295 No-DAC (Modified GRF) Plus Ipamorelin

This is the most common starting protocol because it preserves pulsatile GH physiology. Both peptides have short active windows, so they are injected together.

• Dose: Ipamorelin 100 to 300 mcg combined with CJC-1295 no-DAC 100 to 300 mcg per injection
• Frequency: 1 to 3 times daily
• Timing: Inject on an empty stomach or at least 2 hours after a meal; insulin blunts GH release [6]. The pre-sleep injection is considered highest-yield because it coincides with the largest endogenous GH pulse, which normally occurs 60 to 90 minutes after sleep onset [7]
• Cycle length: 3 to 6 months followed by a 4 to 8 week washout

Many practitioners start at 100 mcg of each peptide once daily at bedtime, then increase to twice or three-times daily at 4 weeks if IGF-1 is not trending upward by at least 20% above baseline.

Protocol B: CJC-1295 DAC Plus Ipamorelin

The DAC form is injected once or twice weekly while ipamorelin is still injected daily to provide the second signal on non-DAC days. This produces a more sustained IGF-1 elevation rather than sharp daily GH pulses.

• CJC-1295 DAC dose: 1,000 to 2,000 mcg once weekly or 500 to 1,000 mcg twice weekly, subcutaneous
• Ipamorelin dose: 100 to 200 mcg once or twice daily on all days
• Cycle length: 12 to 20 weeks

The sustained IGF-1 elevation from the DAC form may be more appropriate for recovery and connective tissue goals, whereas Protocol A's sharper daily pulses may better mimic normal physiology for general anti-aging applications. Neither claim rests on head-to-head RCT data.

Injection Technique

Both peptides are injected subcutaneously, typically into the abdomen, flanks, or thighs. Reconstitution uses bacteriostatic water; a standard preparation mixes 2 mL bacteriostatic water with 5 mg of lyophilized peptide to yield a 2,500 mcg/mL concentration. Syringes are insulin-style (29 to 31 gauge, 0.3 mL). Sites should be rotated to avoid lipodystrophy [8].

Timing, Nutrition, and Lifestyle Interactions

The Glucose-GH Axis

Elevated blood glucose suppresses GH release directly through somatostatin. A 2013 study published in the Journal of Clinical Endocrinology and Metabolism confirmed that oral glucose loading suppresses GH to below 1 ng/mL for 2 to 3 hours in healthy adults [6]. Injecting either peptide within 1 to 2 hours of a carbohydrate-rich meal likely blunts the GH response substantially. Fasted injections, especially the pre-sleep dose, are therefore standard practice.

Sleep and the Nocturnal GH Pulse

The pituitary releases approximately 70% of daily GH during slow-wave sleep [7]. Timing the ipamorelin-CJC-1295 injection 30 to 60 minutes before sleep onset amplifies an already-occurring physiological pulse rather than creating a standalone pharmacological one. Patients with poor sleep architecture may see attenuated responses, making sleep hygiene a legitimate clinical variable in protocol design.

Resistance Training Interaction

GH release is also stimulated by heavy resistance exercise. Administering the peptide stack within 30 to 60 minutes before or after training is a common strategy, though the additive benefit over the physiological exercise-induced GH pulse has not been quantified in published trials. IGF-1 signaling downstream of GH is required for satellite cell activation and muscle protein synthesis [9], which is the mechanistic rationale practitioners cite.

Expected Outcomes and Timeline

IGF-1 as the Primary Biomarker

IGF-1 is the most clinically useful proxy for cumulative GH secretion because it integrates GH pulses over 24 hours and has a half-life of roughly 15 to 20 hours [10]. In Teichman et al.'s CJC-1295 DAC trial, IGF-1 rose 28 to 89% from baseline depending on dose, which provides the best available human benchmark [2]. Ipamorelin alone has been shown in preclinical models to raise IGF-1 in a dose-dependent manner [1]. The stack is expected to produce a larger IGF-1 rise than either agent alone, but exact percentage increases in combination remain unpublished.

What to Realistically Expect

Practitioners typically observe three categories of reported benefit, drawn from patient-reported outcomes and clinical observation rather than RCTs:

• Sleep quality: Improved deep sleep reported within 2 to 4 weeks, likely mediated by GH's direct CNS effects [7]
• Body composition: Gradual lean mass accretion and mild fat reduction over 8 to 16 weeks, mechanistically consistent with IGF-1's anabolic and lipolytic signaling [9]
• Recovery: Reduced muscle soreness and faster return to baseline between training sessions, consistent with GH's role in collagen and connective tissue turnover [11]

None of these outcomes has been confirmed in a powered RCT of the combination. Patients should understand this clearly before starting.

When IGF-1 Does Not Rise

If IGF-1 fails to rise by at least 20% after 8 weeks at full dose, possibilities include: subtherapeutic product quality (peptides are not FDA-approved and potency is not independently verified), injection errors (wrong reconstitution ratio, improper storage above 8 degrees Celsius), persistent postprandial hyperglycemia blunting response, or underlying pituitary pathology that warrants formal endocrine evaluation [10].

Safety Profile and Monitoring

Ipamorelin Safety Data

The selectivity data for ipamorelin are more reassuring than for older GHRPs. In rat studies at 200 mcg/kg, cortisol and prolactin were not significantly elevated, contrasting sharply with GHRP-6 at the same dose [1]. Human clinical safety data beyond pharmacokinetic studies are limited. The most commonly reported adverse effects in practitioner reports include mild water retention (hands, feet, ankles) from GH-driven aldosterone interaction, transient fatigue, and injection-site reactions [8].

CJC-1295 Safety Data

Teichman et al. Reported that CJC-1295 DAC was generally well tolerated in their N=65 trial. Adverse events were mostly mild: flushing (7%), headache (10%), and dizziness (7%), occurring shortly after injection and resolving within hours [2]. No serious adverse events were attributed to the drug in that trial.

Potential Risks of GH-Axis Stimulation

Any protocol that chronically elevates GH and IGF-1 carries theoretical risks analogous to exogenous GH therapy: insulin resistance, fluid retention, carpal tunnel syndrome, and theoretical promotion of pre-existing neoplastic tissue [5]. The 2011 Endocrine Society clinical practice guideline on adult GH deficiency states that GH therapy is contraindicated in patients with active malignancy and requires careful monitoring of IGF-1 to avoid supraphysiological levels [5]. These same principles apply to secretagogue stacks, even though the mechanism differs.

Recommended Monitoring Schedule

| Timepoint | Labs | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, CBC, CMP, cortisol (AM) | | 6 to 8 weeks | IGF-1, fasting glucose | | 12 weeks | IGF-1, fasting glucose, HbA1c | | End of cycle | Full panel repeat |

Target IGF-1 range during therapy: age-adjusted mid-normal (typically 150 to 300 ng/mL for adults aged 30 to 50) [5]. Levels above the upper limit of normal for age warrant dose reduction or temporary discontinuation.

Regulatory and Compounding Status

Neither ipamorelin nor CJC-1295 is FDA-approved for any indication in humans. Ipamorelin does not appear on the FDA's approved drug list [12]. CJC-1295 is likewise not approved. Both have appeared on FDA warning letters and compounding guidance documents as substances that do not meet the criteria for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [12].

As of 2024, the FDA placed several peptides on a list of bulk drug substances that may not be compounded, and practitioners should verify current compounding pharmacy legal status before prescribing. Patients obtaining these peptides from non-pharmacy online sources have no assurance of sterility, potency, or accurate labeling, which represents a patient safety concern independent of the pharmacology [12].

Stacking With Other Therapies

With Testosterone Replacement Therapy (TRT)

Some practitioners combine this peptide stack with TRT in men with documented hypogonadism. Testosterone and GH act through independent anabolic pathways, and no pharmacokinetic interaction is expected. The additive body composition benefit has mechanistic support [9] but no RCT evidence in that specific combination. IGF-1 monitoring remains important because testosterone itself modestly raises IGF-1 [10].

With BPC-157

BPC-157, a pentadecapeptide, is sometimes added for connective tissue and gut healing goals. No published pharmacokinetic interaction data exist between BPC-157 and the ipamorelin-CJC-1295 stack. The injections are typically kept separate in timing and site to reduce any local interaction, though this is convention rather than evidence-based practice [11].

With Sermorelin

Adding sermorelin, another GHRH analogue, to CJC-1295 provides no clear additive mechanism because both target the same GHRH receptor. Using both simultaneously is not standard practice and would likely produce receptor competition rather than benefit [4].